Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Sutamtewagul, Grerk
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome	Recruiting	3	550	Europe, Canada, US, RoW	Tamibarotene, SY-1425, Placebo, Azacitidine	Syros Pharmaceuticals	Myelodysplastic Syndromes	11/24	02/29
OV-AML-1231, NCT06384261: A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy	Recruiting	2	120	Europe, Canada, US	Cusatuzumab, OV-1001, Venetoclax, Azacitidine	OncoVerity, Inc.	Leukemia, Myeloid, Acute	01/27	06/27
Hagen, Jussara
SGNBB228-001, NCT05571839: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors	Recruiting	1	275	Europe, Canada, US	PF-08046049	Seagen Inc.	Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma	11/26	11/27